homepage-top-section

The regulator has approved a supplemental new drug application (sNDA) for Recarbrio to treat patients 18 years of age and older with HABP/VABP caused due to susceptible Gram-negative

The partnership will combine Accent’s expertise in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s advanced knowledge in oncology. Accent Therapeutics CEO Shakti Narayan

The approval, which is based on results from the phase 3 BEACON CRC trial, enables to market Braftovi plus cetuximab in 27 EU member states, as well as

The regulator has provided the company with the permission to submit an investigational new drug application (IND) to use FSD-201 for the treatment of Covid-19, the disease resulted

The multi-centre, randomised, double-blind and parallel-group clinical study will evaluate the efficacy and safety of once-weekly subcutaneous injections of PB1046 in hospitalised Covid-19 patients at high risk for

The deal value of $500m will be based on the achievement of certain predetermined regulatory and commercial milestones. The transaction will provide Shionogi with global rights to Tetra’s

The IND has been submitted for a multinational phase 2b/3 study to assess re-purposed drug NP-120 (Ifenprodil) as a potential therapeutic treatment for patients with Covid-19. Ifenprodil, an

The approval enables to use of Kynmobi sublingual film for the acute and intermittent treatment of off episodes in patients with Parkinson’s disease. Kynmobi, a novel formulation of

Octagam 10% is an immune globulin intravenous (human) liquid preparation designated to treat chronic immune thrombocytopenic purpura (ITP) in adults. According to the company, the primary objective of